LNX1-AS2 as a Key Prognostic and Immunotherapy Response Biomarker for Lung Adenocarcinoma
A noteworthy relationship was established among increased LNX1-AS2 expression in LUAD patients, unfavorable prognosis, and heightened immune infiltration. These findings suggest that the LNX1-AS2 gene could serve as a valuable prognostic indicator for LUAD and a potential predictor of response to immunotherapy.
Authors
- X. Wang (ORCID: https://orcid.org/0009-0003-1472-3920)
- Xiaoying Zhang (ORCID: https://orcid.org/0009-0005-2449-7108)
- Dongbing Li (ORCID: https://orcid.org/0000-0002-5227-9643)
- Guangyi Li (ORCID: https://orcid.org/0000-0002-0203-340X)
- Guanzhong Yan (ORCID: https://orcid.org/0000-0002-7182-4694)
Institutions
- Shandong University (CN)
- Qingdao Eighth People's Hospital (CN)
Publication Details
- Journal
- Current Medicinal Chemistry
- Published
- 2024-11-05
- DOI
- https://doi.org/10.2174/0109298673321029241015153958
- Citations
- 2
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.47